Retrospective side effect profiling of the metastatic melanoma combination therapy Ipilimumab-Nivolumab using adverse event data

• Verfasst von: Soldatos, Theodoros [VerfasserIn]
• Verfasst von: Dimitrakopoulou-Strauss, Antonia [VerfasserIn]
• Verfasst von: Larribere, Lionel [VerfasserIn]
• Verfasst von: Hassel, Jessica C. [VerfasserIn]
• Verfasst von: Sachpekidis, Christos [VerfasserIn]
• Titel: Retrospective side effect profiling of the metastatic melanoma combination therapy Ipilimumab-Nivolumab using adverse event data
• Verf.angabe: Theodoros G. Soldatos, Antonia Dimitrakopoulou-Strauss, Lionel Larribere, Jessica C. Hassel, Christos Sachpekidis
• E-Jahr: 2018
• Jahr: 31 October 2018
• Umfang: 13 S.
• Fussnoten: Gesehen am 18.12.2019
• Titel Quelle: Enthalten in: Diagnostics
• Ort Quelle: Basel : MDPI, 2011
• Jahr Quelle: 2018
• Band/Heft Quelle: 8(2018,4) Artikel-Nummer 76, 13 Seiten
• ISSN Quelle: 2075-4418
• DOI: doi:10.3390/diagnostics8040076
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1685935540

Abstract

Recent studies suggest that combining nivolumab with ipilimumab is a more effective treatment for melanoma patients, compared to using ipilimumab or nivolumab alone. However, treatment with these immunotherapeutic agents is frequently associated with increased risk of toxicity, and (auto-) immune-related adverse events. The precise pathophysiologic mechanisms of these events are not yet clear, and evidence from clinical trials and translational studies remains limited. Our retrospective analysis of ~7700 metastatic melanoma patients treated with ipilimumab and/or nivolumab from the FDA Adverse Event Reporting System (FAERS) demonstrates that the identified immune-related reactions are specific to ipilimumab and/or nivolumab, and that when the two agents are administered together, their safety profile combines reactions from each drug alone. While more prospective studies are needed to characterize the safety of ipilimumab and nivolumab, the present work constitutes perhaps the first effort to examine the safety of these drugs and their combination based on computational evidence from real world post marketing data.